Articles Tagged with Zantac carcinogen

More than 70,000 Zantac Lawsuits to Move Forward in Delaware State Court

Published on: June 28, 2024 | By James Hodges

A Delaware Superior Court Judge has allowed roughly 75,000 plaintiffs to be heard in Delaware courts regarding whether the drug Zantac caused cancer. This is a massive turn of events, as nearly 50,000 similar lawsuits were dismissed in federal courts just two years ago. In 2022, the federal judge in the multidistrict litigation in Florida determined that the expert witness reports and testimony were not based on adequate science. Judge Medinilla, by contrast, ruled that the expert testimony should be heard in court with regard to the causation between Zantac and cancer. Ultimately, she determined that the strength of each side’s scientific arguments should be heard and considered by juries.

History of Zantac Regulation and Litigation

The heartburn medication commonly known as Zantac has been available on the market for decades, and was once one of the world’s top selling drugs. It is used to treat many gastrointestinal disorders including heartburn, duodenal ulcers, gastroesophageal reflux disease, and esophagitis. Zantac is known to contain an active ingredient called ranitidine. This molecule has been shown to degrade into NDMA (N-Nitrosodimethylamine) over time and when exposed to heat. NDMA is a known carcinogen.

Zantac Litigation Focused on Bladder, Liver, Esophageal, Gastric, and Pancreatic Cancers

Published on: February 15, 2022 | By Clay Hodges

In any product liability litigation, the injured person must ultimately prove that the injury was caused by the defective product (legal causation). A relatively easy example is when a lamp explodes and burns an individual, and in the post-explosion investigation the plaintiff discovers the lamp’s wiring was faulty and unreasonably dangerous. In the Zantac (ranitidine) multi-district litigation (MDL), thousands of plaintiffs have come forward alleging that use of the heartburn medication caused their various cancers. I discussed how Zantac is alleged to cause cancer in previous posts. You can start here if interested. In a nutshell, however, studies have shown that Zantac may contain potentially dangerous levels of NDMA (N-Nitrosodimethylamine), which is a likely carcinogen in humans.

There are several ways that NDMA is thought to be present in Zantac medication, which you can read about here. The larger point is simple: you do not want to ingest NDMA, and you certainly do not want to ingest large amounts of NDMA, especially for months or years. Remember, millions of people have taken Zantac or the generic ranitidine, some for many years, so the potential consumer-health risk is widespread. Zantac has been recalled.

Because these studies link Zantac to NDMA, plaintiffs who used Zantac and later developed one of several cancers (reasonably) came forward and filed lawsuits against the manufacturers of Zantac. The original Master Complaint listed at least sixteen different cancers, with indications that the list was not exhaustive.

Court Rulings in Zantac Litigation Could Toss Many Cases: What This Means for You

Published on: January 20, 2021 | By Clay Hodges

After news broke that Zantac (the brand name for ranitidine) was linked to cancer, a large wave of lawsuits started making their way into state and federal courts. Many of these cases have been consolidated into the Zantac multi-district litigation, or MDL 2924.

The Zantac MDL is still in the early stages of litigation, but the court just handed down two major decisions that could dramatically undermine a majority of the cases and claims.

We’ll go over these two decisions, but before we do, we need to provide a little context. We’ll start with outlining the defendants and claims in the Zantac MDL, then discuss a legal concept called “preemption.”

Zantac Litigation Master Complaint Key Points, Part 1: The Parties Involved

Published on: August 27, 2020 | By Clay Hodges

If you truly want to learn about a particular litigation involving a defective product (such as Zantac), the best place to start is the Master Complaint. This is the lengthy comprehensive document filed by the plaintiffs in a multi-district litigation involving a defective product. This does not mean the case is a class action. Most product liability cases are not class action lawsuits but are rather individual lawsuits gathered together in a “multi-district litigation or MDL.” These cases are transferred from across the country in one court, where one federal court judge will oversee the litigation until either (1) a global settlement is reached or (2) the cases are ready to be returned to the their home courts for trial.

The multi-district litigation involving the drug Zantac is located in the Southern District of Florida (MDL No. 2924). On June 22, 2020 the plaintiffs filed their Master Personal Injury Complaint. It is a long and detailed document, and it is worth your time to read if you have taken Zantac over an extended period, and certainly if you have taken Zantac and later developed cancer.

Many people, understandably, are not thrilled to read a 158-page legal document. So today and in the days to follow I am going to write up key bullet points from the Zantac Master Complaint. First, a few general guidelines: a complaint is the document a plaintiff files in a court to start a civil case. It can be a single page, alleging that the neighbor’s dog bit the plaintiff and caused injuries, or it can be hundreds of pages long, involving many defendants and many claims. The key thing to remember is that the complaint involves allegations, not proven facts. It may well be that every word of a complaint is true and that the plaintiffs provide compelling evidence for every allegation at trial. But at the start of a civil case the complaint should be understood as a series of allegations, which the defendants are allowed to deny and which they often deny. And that’s where the courts and juries come in: to figure out which side has proven its case.

Zantac: Overview of Recall and Lawsuits Due to Cancer-Causing NDMA

Published on: January 19, 2020 | By Clay Hodges

Many of us suffer from heartburn, and one of the most popular ways to treat it is by taking Zantac. Until recently, Zantac was considered a very safe medication and was available without a prescription.

Given how well it worked, along with its affordable price and the perception of safety, hundreds of thousands of people, if not millions, took Zantac. In the fall of last year, the US Food and Drug Administration (FDA) reported that this popular drug might contain N-Nitrosodimethylamine (NDMA), a likely cancer-causing substance.

The past few months have resulted in mass voluntary recalls and a rush of FDA updates and reports about the possible dangers of taking Zantac and what it means for consumers. This blog post will attempt to summarize what’s going on and briefly discuss what happens next.

★★★★★

I was involved in a case for the faulty hip replacements. Clay Hodges represented me. I can't say enough about how much he has helped me. Clay was able to win multiple settlements on my behalf with most of them being the maximum amount able to be awarded. Matt J.

Clay, thank you sir for making a disheartening experience at least palatable, you and your staff were honest, caring and understanding through the entire process of my wife’s hip replacements, while monetary settlements never make the pain and suffering end, it sometimes is the only way people can fight back to right a wrong. J. V.

We are absolutely pleased with how Clay Hodges handled my husband’s hip replacement claim. He always kept us informed of the progress. And, his work resulted in a settlement which we are extremely pleased. Thank you, Clay! Carol L. & Norm L.